/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

KYMERA THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$64.01 0.0268(2.68%) KYMR at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 64.86
Highest Today 66.51
Today’s Open 65.2
Prev. Close 64.27
52 Week High 68.80
52 Week Low 19.45
Day’s Range: Low 64.86 High 66.51
52-Week Range: Low 19.45 High 68.80
1 day return -
1 Week return -2.66
1 month return +10.2
3 month return +56.34
6 month return +49.07
1 year return +43.15
3 year return +126.44
5 year return +21.61
10 year return -

Institutional Holdings

T. Rowe Price Associates, Inc. 9.59

Baker Bros Advisors LP 9.30

venBio Select Advisor LLC 9.17

Vanguard Group Inc 7.86

Bvf Inc 7.70

FMR Inc 7.60

Wellington Management Company LLP 7.51

BlackRock Inc 5.80

Siren, L.L.C. 4.79

US Small-Cap Growth II Equity Comp 4.06

T. Rowe Price New Horizons 3.73

Vanguard Health Care Inv 3.34

Fidelity Growth Compy Commingled Pl S 3.29

Vanguard Total Stock Mkt Idx Inv 2.63

Fidelity Growth Company Fund 2.30

State Street Corp 2.17

Vanguard Small Cap Index 2.03

Capital Research Global Investors 1.77

T. Rowe Price Health Sciences 1.69

Geode Capital Management, LLC 1.67

iShares Russell 2000 ETF 1.58

American Funds SMALLCAP World A 1.56

Vanguard Explorer Inv 1.37

Driehaus Capital Management LLC 1.31

T. Rowe Price New Horizons Tr-A 1.30

Jennison Associates LLC 1.15

UBS Asset Mgmt Americas Inc 1.15

Vanguard Small Cap Growth Index Inv 1.14

Redmile Group, LLC 1.12

Merck & Co Inc 1.08

COMMODORE CAPITAL LP 1.05

Deerfield Management Co 0.91

T. Rowe Price Integrated US SmCapGrEq 0.80

Dimensional Fund Advisors, Inc. 0.79

Eventide Healthcare & Life Sciences I 0.79

Vanguard Institutional Extnd Mkt Idx Tr 0.78

T. Rowe Price Integrated US Sm Gr Eq 0.75

Jennison Health Sciences Equity 0.73

PGIM Jennison Health Sciences Z 0.73

SPDR® S&P Biotech ETF 0.68

Market Status

Strong Buy: 14

Buy: 3

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4624.16 M

PB Ratio 5.1613

PE Ratio 0.0

Enterprise Value 4462.21 M

Total Assets 978.04 M

Volume 508796

Company Financials

Annual Revenue FY23:46846000 46.8M, FY22:46826000 46.8M, FY21:72832000 72.8M, FY20:34034000 34.0M, FY19:2934000 2.9M

Annual Profit FY23:null 0.0M, FY22:46826000 46.8M, FY21:72832000 72.8M, FY20:34034000 34.0M, FY19:2934000 2.9M

Annual Net worth FY23:-167459000 -167.5M, FY22:-151831000 -151.8M, FY21:-97995000 -98.0M, FY20:-43945000 -43.9M, FY19:-41292000 -41.3M

Quarterly Revenue Q3/2025:2764000 2.8M, Q2/2025:11476000 11.5M, Q1/2025:22100000 22.1M, Q3/2024:3741000 3.7M, Q2/2024:25650000 25.7M

Quarterly Profit Q3/2025:-71330000 -71.3M, Q2/2025:9392000 9.4M, Q1/2025:22100000 22.1M, Q3/2024:1741000 1.7M, Q2/2024:23750000 23.8M

Quarterly Net worth Q3/2025:-82175000 -82.2M, Q2/2025:-76614000 -76.6M, Q1/2025:-65581000 -65.6M, Q3/2024:-62487000 -62.5M, Q2/2024:-42062000 -42.1M

Fund house & investment objective

Company Information Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 225

Industry Biotechnology

CEO Dr. Nello Mainolfi M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow